Acrux patent triggers milestone payment
Friday, 19 November, 2004
Acrux (ASX:ACR) has received a US$250,000 milestone payment from its partner Vivus triggered by the granting of a US patent extending the coverage of its proprietary transdermal drug delivery system.
The patent provides protection for transdermal drug delivery systems consisting of an effective amount of a therapeutic drug, a dermal penetration enhancer and a volatile liquid, with an area of application that becomes touch-dry within 3 minutes of administration.
CEO Igor Gonda said the patent claims provided strategic protection for the product compared to other transdermal drug delivery systems including patches and gels. Acrux has similar patents pending in other international markets.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
